Echosens and Boehringer Ingelheim Expand Partnership for MASH Diagnosis

June 10, 2025
Echosens and Boehringer Ingelheim have expanded their collaboration to enhance the diagnosis and care of metabolic dysfunction-associated steatohepatitis (MASH), focusing on early detection and non-invasive technologies.
Echosens and Boehringer Ingelheim Expand Partnership for MASH Diagnosis

Echosens and Boehringer Ingelheim have announced an expansion of their long-standing partnership to advance the diagnosis and care of metabolic dysfunction-associated steatohepatitis (MASH), announced in a press release. This collaboration aims to address the urgent need for early screening and diagnosis of MASH, a chronic liver disease affecting over 250 million people worldwide.

The partnership will focus on raising awareness among patients, healthcare professionals, and policymakers about the importance of early detection. It will also promote the adoption of streamlined care pathways and expand access to non-invasive technologies (NITs) for MASH diagnosis. Echosens' FibroScan®, a non-invasive liver assessment technology, will continue to play a crucial role in Boehringer Ingelheim's ongoing research and clinical trials.

By combining their diagnostic and therapeutic expertise, the two companies aim to close gaps in awareness and clinical adoption, ultimately improving liver health outcomes globally.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

07/29
Arbital Health Secures $31M to Expand AI-Powered Healthcare Platform
07/29
Proprio Joins AWS Partner Network to Enhance Surgical AI Platform
07/29
Briya Launches AI Platform for Medical Research
07/29
Johnson & Johnson Introduces AI-Powered VIRTUGUIDE System for Bunion Surgery
07/29
Machine Learning Model Predicts No-Shows in Primary Care

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like